A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

被引：0
|
作者：
Shan, Yan-Shen
Li, Chung-Pin
Khan, Gazala
Lee, Woo Jin
Choi, Hye Jin
Chang, Heung-Moon
Lee, Moon Hee
Wallmark, John M.
Chen, Pei-Ni
机构：
[1] NCKU & NCKUH, Coll Med, Tainan, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei, Taiwan
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[5] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[7] Inha Univ, Dept Internal Med, Coll Med, Incheon, South Korea
[8] Associates Oncol Hematol PC, Rockville, MD USA
[9] Golden Biotechnol Corp, New Taipei City, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-199-2823; 298-145-222-184-1022-9122; 283-2494; 261-492-2769; 298-145-222-184-1022-9124; 298-145-222-184-1022-8913; 283-237-267; 4; 3; 2; 219; 3618; 176; 12; 6; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.648
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：648 / 648
页数：1
相关论文
共 50 条
  • [21] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [22] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [23] A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
    Pelzer, Uwe
    Bendell, Johanna C.
    Womack, Mark S.
    Bahary, Nathan
    Macarulla, Teresa
    Borazanci, Erkut Hasan
    Levy, Donna Elise
    Mo, Gary
    Ramage, Samuel Cowan
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [24] Final report: A phase I trial of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
    Soares, Heloisa P.
    Al-Toubah, Taymeyah E.
    Kim, Richard D.
    Kim, Jongphil
    Lewis, Neron K.
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [25] A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
    Soares, Heloisa P.
    Springett, Gregory M.
    Kim, Richard D.
    Williams-Elson, Irene
    Miller, Kara
    Kothari, Nishi
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [26] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
    Ramanathan, Ramesh K.
    Lee, Peter
    Seng, John E.
    Anthony, Stephen Patrick
    Rosen, Peter J.
    Mena, Raul R.
    Picozzi, Vincent J.
    Sachdev, Jasgit C.
    Larson, Tim
    Korn, Ronald
    Jameson, Gayle S.
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Leach, Joseph W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [27] Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer
    Ramanathan, Ramesh K.
    Lee, Peter
    Leach, Joseph W.
    Anthony, Stephen Patrick
    Weiss, Glen J.
    Rosen, Peter J.
    Picozzi, Vincent J.
    Sachdev, Jasgit C.
    Larson, Tim
    Korn, Ronald
    Hu, Chengcheng
    Jameson, Gayle S.
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Seng, John E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [28] Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
    Thapaliya, P.
    Kundranda, M. N.
    Curtis, K. K.
    Callister, M. D.
    Ashman, J. B.
    Collins, J.
    Moss, A.
    Mekeel, K. L.
    Silva, A. C.
    Borad, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase II trial of biologically optimized schedule of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer
    Noonan, Anne M.
    Noonan, Anne M.
    Abushahin, Laith I.
    Wei, Lai
    Malalur, Pannaga G.
    Manne, Ashish
    Mittra, Arjun
    Roychowdhury, Sameek
    Jin, Ning
    Hays, John L.
    Babcook, Melissa A.
    Risch, Zachary
    Rahman, Shafia
    Hazard, Brooke
    Williams, Terence Marques
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345